Baird served as the sole manager of this transaction
AboutExact Sciences Corporation (NASDAQ: EXAS) (or the “Company”) recently completed a 4,200,000 share follow-on offering of its common stock at $4.50 per share. Gross proceeds from the offering totaled approximately $18.9 million. The Company intends to use the proceeds from the offering for general corporate and working capital purposes, including the funding of strategic initiatives that the Company may undertake from time to time, for product development and the furtherance of the Company’s efforts to obtain FDA clearance for its stool-based DNA colorectal cancer screening product. The Company has granted Baird an option to purchase an additional 630,000 shares to cover over-allotments.
Exact Sciences Corporation is a molecular diagnostics company focused on colorectal cancer. The Company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
For additional information about this transaction, please contact:
- April 2010
- Exact Sciences Corporation
- Target Location
- North America